Astrazeneca (AZN) Capital Leases (2012 - 2026)
Astrazeneca (AZN) posted quarterly Capital Leases of -$94.0 million for Q1 2026, down 16.05% year-over-year from -$112.0 million in Q1 2025, and up 74.73% quarter-over-quarter from -$372.0 million in Q4 2025.
Astrazeneca (AZN) Capital Leases (2012 - 2026) Analysis & Trends
Astrazeneca's Capital Leases history runs 12 years deep, the most recent figure standing at -$94.0 million for Q1 2026.
- In Q1 2026, Capital Leases fell 16.05% year-over-year to -$94.0 million; the TTM figure through Mar 2026 stood at -$94.0 million (down 16.05% YoY), while the FY2025 annual figure was -$372.0 million, down 17.72% from the prior year.
- Capital Leases for Q1 2026 stood at -$94.0 million, up from -$372.0 million in the prior quarter.
- The five-year high for Capital Leases was -$67.0 million in Q1 2023, with the low at -$372.0 million in Q4 2025.
- The 5-year median for Capital Leases is -$134.0 million (2022), against an average of -$167.8 million.
- The sharpest annual moves came in 2022 and 2023: Capital Leases slumped 87.32% in 2022, then advanced 9.46% in 2023.
- Astrazeneca's Capital Leases stood at -$134.0 million in 2022, then advanced by 3.73% to -$129.0 million in 2023, then plunged by 144.96% to -$316.0 million in 2024, then fell by 17.72% to -$372.0 million in 2025, then surged by 74.73% to -$94.0 million in 2026.
- Business Quant data shows AZN's Capital Leases at -$94.0 million in Q1 2026, -$372.0 million in Q4 2025, and -$273.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -94.00 Mn |
| Dec 31, 2025 | -372.00 Mn |
| Sep 30, 2025 | -273.00 Mn |
| Jun 30, 2025 | -184.00 Mn |
| Mar 31, 2025 | -81.00 Mn |
| Dec 31, 2024 | -316.00 Mn |
| Sep 30, 2024 | -233.00 Mn |
| Jun 30, 2024 | -150.00 Mn |
| Mar 31, 2024 | -74.00 Mn |
| Jun 30, 2023 | -129.00 Mn |
| Mar 31, 2023 | -67.00 Mn |
| Jun 30, 2022 | -134.00 Mn |
| Mar 31, 2022 | -74.00 Mn |
| Dec 31, 2021 | -240.00 Mn |
| Sep 30, 2021 | -173.00 Mn |
| Jun 30, 2021 | -111.00 Mn |
| Mar 31, 2021 | -39.50 Mn |
| Dec 31, 2020 | -158.78 Mn |
| Sep 30, 2020 | -157.00 Mn |
| Jun 30, 2020 | -77.17 Mn |